Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Assembly Biosciences (ASMB) Equity Average (2016 - 2025)

Historic Equity Average for Assembly Biosciences (ASMB) over the last 11 years, with Q3 2025 value amounting to $100.4 million.

  • Assembly Biosciences' Equity Average rose 23088.08% to $100.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.4 million, marking a year-over-year increase of 23088.08%. This contributed to the annual value of $37.2 million for FY2024, which is 3983.89% down from last year.
  • As of Q3 2025, Assembly Biosciences' Equity Average stood at $100.4 million, which was up 23088.08% from $22.6 million recorded in Q2 2025.
  • Over the past 5 years, Assembly Biosciences' Equity Average peaked at $243.9 million during Q1 2021, and registered a low of $22.6 million during Q2 2025.
  • Over the past 5 years, Assembly Biosciences' median Equity Average value was $76.5 million (recorded in 2023), while the average stood at $101.1 million.
  • Its Equity Average has fluctuated over the past 5 years, first tumbled by 5730.13% in 2023, then surged by 23088.08% in 2025.
  • Assembly Biosciences' Equity Average (Quarter) stood at $196.8 million in 2021, then crashed by 52.98% to $92.5 million in 2022, then crashed by 55.25% to $41.4 million in 2023, then fell by 28.32% to $29.7 million in 2024, then surged by 238.26% to $100.4 million in 2025.
  • Its Equity Average stands at $100.4 million for Q3 2025, versus $22.6 million for Q2 2025 and $30.2 million for Q1 2025.